Telix is acquiring ITM Isotope Technologies Munich for $1.65 billion upfront, made up of $1.25 billion in Telix shares valued at $11.84 each on a 30-day VWAP, $302 million in assumed net debt and $96 million for management equity rollover and transaction expenses, plus up to $700 million in regulatory and commercial milestones. ITM brings EndolucinBeta, a radiopharmaceutical precursor, and Phase III ITM-11 in gastroenteropancreatic neuroendocrine tumours, alongside programmes in glioblastoma, CAIX-expressing solid tumours, prostate and ovarian cancer. ITM shareholders will own 23.7% of a combined company that expects more than $1.3 billion in 2026 revenue.

Seventy percent committed at signing, and the seller took most of it in the buyer’s own paper.

The milestone schedule is the part to read, because every date is written down: $100 million for ITM-11 approval in G1 to G2 GEP-NETs by the end of FY2027, $100 million in G2 to G3 by FY2030, $50 million in lung NETs by FY2031, and up to $450 million only if ITM-11 passes $150 million in global sales in FY2030. Nearly two thirds of the contingent value sits on one sales threshold four years out. The same week supplied a reason to discount it. FDA gave Lantheus final approval for Bravnetsa, the first radioligand approved as therapeutically equivalent to Lutathera through the generic pathway, so ITM-11 will launch into an SSTR market where the reference product already has a generic.

Grünenthal is buying Stivarga (regorafenib), Bayer’s oral multikinase inhibitor, approved in more than 90 countries for previously treated metastatic colorectal cancer, gastrointestinal stromal tumours after imatinib and sunitinib, and hepatocellular carcinoma after sorafenib. Bayer receives up to €375 million, about $430.65 million, upfront. Closing is expected by the end of 2026 or early 2027.

Every indication on the label sits after other therapies have failed. That is what a tail asset looks like.

The two approved-asset deals of the week ran in opposite currencies. Telix paid mostly in stock for a pipeline with a precursor business attached; Grünenthal paid cash for a product whose value is its existing prescriptions. A buyer paying the whole price at signing is buying cash flow it can model, not a development option. For Bayer it is portfolio clearance; for Grünenthal, which built its business in pain, a 90-country oncology product is as much a commercial infrastructure purchase as a revenue one.

InnoCare granted Lilly rights to up to five therapies for up to $100 million in upfront and near-term payments, with no breakout, and $3.25 billion in milestones. Atavistik Bio took $70 million upfront from Roche against $1.97 billion for allosteric small molecules in cardiovascular, renal and metabolic disease. Earendil Labs took $55 million from Genentech against more than $1.5 billion for AI-discovered bispecifics. Nanexa granted Novo Nordisk its PharmaShell delivery platform for up to €1.165 billion, including €615 million in upfront, development and regulatory payments with no breakout. Envisagenics signed an option deal with Boehringer Ingelheim worth more than $1 billion, and Amberstone took $4 million from Henlius against $888 million, while Iambic’s AbbVie deal disclosed nothing.

Three percent committed at signing, where anyone said. The rest is a menu of futures.

The upfront ratio says buyers are paying for access to a process, not to a molecule. A platform deal at 3% upfront is an option premium, and it should be modelled as one, because the headline total assumes every target reaches market. Note the buyers: Roche twice on the same day through two separate entities, then Lilly, Novo and Boehringer. AI-enabled discovery sits in three of the seven. Nanexa is the outlier to isolate: a long-acting injectable technology for peptides in obesity is a lifecycle play for Novo’s own franchise rather than discovery.

DRI Healthcare Trust is buying Bain Capital and NovaQuest’s US royalty rights to tavapadon, AbbVie’s once-daily D1/D5 partial agonist in Parkinson’s disease, for $316 million at closing. DRI receives mid-single-digit to low-double-digit tiered royalties on US net sales, sales milestones and four annual fixed payments of $23.4 million after approval, with total payments capped at $437.5 million. Ligand bought Santen’s EMEA royalty and milestone rights to Ryjunea, a low-dose atropine eye drop for paediatric myopia, for $23 million, and committed up to $41 million in four tranches for AvenCell’s royalties on two CAR-T programmes, plus up to $6 million in AvenCell’s Series C.

The cap is the tell: 1.38 times the money at most, on a drug whose price benchmark arrived before its price.

The cap turns the tavapadon purchase into something closer to credit. Four fixed payments totalling $93.6 million arrive on approval regardless of sales, and the whole return stops at $437.5 million. DRI has priced a ceiling and accepted launch risk for the floor. The timing is the story: ICER’s draft report of 16 September found tavapadon not cost-effective at a $15,000 placeholder and set an adjunctive benchmark of $4,764 to $6,861 a year. Bain and NovaQuest sold after that report and before AbbVie names a price; Week 33 logged two royalty sales, this week three.

Lexeo Therapeutics agreed to acquire Mantle Therapeutics for $8.3 million upfront in cash and equity and up to $13.0 million in milestones, adding four frataxin programmes led by LX3010, an oral HDAC inhibitor and Nrf2 activator with early data in 11 patients. The same day it signed three undisclosed collaborations: Weill Cornell Medicine to test intra-cisternal delivery of LX2006 in large animals, an option from Vivet Therapeutics on VTX-PID, an IgG-cleaving protease intended to allow AAV redosing, and access to Apertura’s TfR1-binding CNS capsid. Elsewhere, Qilu licensed TYK Medicine’s TY-9591 in China for RMB 300 million upfront, then on 21 September terminated a planned RMB 400 million equity subscription. Novotech bought Agilex Biolabs for A$160 million.

Four deals, one disease, one problem: getting a second AAV dose into the brain.

The stack only reads correctly as a set. LX2006 is an AAV gene therapy for Friedreich ataxia cardiomyopathy; the neurological disease needs cerebellar exposure, and AAV cannot normally be given twice because the first dose raises neutralising antibodies. Vivet addresses redosing, Apertura the barrier, Weill Cornell the route, and Mantle buys non-gene-therapy backups, all inside runway guided to 2028. The TYK item is the quiet warning of the week: an equity commitment signed alongside a licence did not survive to close. Nineteen of 34 deals released no terms.